Trial intelligence / Profile preview

Rosmarinic Acid for Prevention of Dementia in Older Adults with Subjective or Mild Cognitive Impairment

jRCTs041180064Active, not recruiting

Start: Jul 2016
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Randomised, double-blind trial in Memory complaint (SMC), Mild Cognitive Impairment (MCI) and Dementia comparing Rosmarinic acid with Placebo (2 arms). Primary endpoint: Change in ADAS-cog score at 48 and 96 weeks. Started Jul 2016; status: active, not recruiting.

Drugs

rosmarinic acid

Conditions

Memory complaint (SMC)Mild Cognitive Impairment (MCI)Dementia

Beyond the preview

Go deeper on jRCTs041180064.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCTs041180064.